According to the new 2021 WHO CNS tumor classification for GBM (Louis et al., 2021), we excluded IDH1-mutant patients from three GBM cohorts and further assessed the Loxl1-based model in IDH1-WT GBM cohorts. This evidence concerns the gene LOXL1 and central nervous system neoplasm.